Theralase Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five
and Six
Toronto, Ontario (FSCwire) - Theralase Technologies Inc.
(“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a
clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds
(“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has
provided an update on patient six, enrolled and treated in the recently completed Phase Ib NMIBC clinical study
(“Study”).
The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and
tolerability, with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint
of efficacy.
The exploratory outcome endpoint was defined as Recurrence-Free Survival (“RFS”), which is the
interval from the day of the treatment to documented recurrence or death from any cause, whichever occurs first. Recurrence is
defined as any new tumour growth (i.e. any biopsy-confirmed new or recurrent tumour), evaluated primarily at ninety (90) days for
the last three patients treated at the Therapeutic Dose (0.70 mg/cm2) and secondarily one hundred and eighty (180)
days post treatment.
Patient number six was treated with the same optimized clinical treatment procedure as patient number five. The
treatment was well tolerated by both patients, who demonstrated no tumour recurrence or presence of disease at the 180 day
clinical and cystoscopy assessment.
This marks the 2nd patient treated at the optimized clinical treatment procedure that has met Study endpoints
demonstrating achievement of the primary, secondary and exploratory endpoints at 180 days post treatment and marks a new
achievement for the Company.
Theralase’s Anti-Cancer Treatment involves the instillation of a water-based solution of Theralase’s lead
anti-cancer PDC, TLD-1433, via a catheter inserted through the urethra into the bladder of the patient, to allow the PDC to be
preferentially absorbed by NMIBC tumours. The bladder is then drained of the solution, flushed with sterile water to remove
non-absorbed solution and refilled with sterile water via a cystoscope. A fibre optic assembly, known as a Laser Emitter emits
laser light to activate TLD-1433, while a Dosimetry Cage detects the emitted laser light, used for patient safety and efficacy.
Both devices are inserted through the cystoscope, with a sole purpose of activating the absorbed PDC to destroy the NMIBC
tumours.
Arkady Mandel, M.D., Ph.D., D. Sc., Interim Chief Executive Officer and Chief Scientific Officer of Theralase
stated, "This is an exciting milestone for our Company, which further solidifies the power of Theralase’s Anti-Cancer Technology.
We look forward to advancing the optimized treatment procedure throughout our planned Phase II study and eventually
commercialization, if these same results are confirmed in the Phase II NMIBC clinical study. The Theralase Anti-Cancer Technology
may very well be the next gold standard in the treatment of NMIBC. Due to the Anti-Cancer Technology’s ability to adapt to
different cancerous targets and pending the successful regulatory approval for the Phase II NMIBC Clinical Study, Theralase
intends to further develop this this technology in the treatment of numerous cancer targets.”
About Theralase Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo
Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. The
Company in its Cool Laser Division designs, manufactures and distributes patented and proprietary super-pulsed cool laser
technology for the treatment of knee pain, and in off-label use, the treatment of numerous nerve, muscle and joint
conditions.
Additional information is available at www.theralase.com and www.sedar.com.
This news release contains "forward-looking statements" which reflect the current expectations of
management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such
statements include, but are not limited to, statements regarding Theralase’s proposed development plans with respect to Photo
Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would",
"could", “should”, "will", "anticipate",
"believe", "plan", "expect", "intend",
"estimate", "potential for" and similar expressions have been used to identify these
forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on
information currently available to management. Forward-looking statements involve significant risks, uncertainties and
assumptions including with respect to the ability of Theralase to: successfully fund and complete
a Phase II NMIBC clinical study, secure the requisite regulatory approvals to commence a
Phase II NMIBC clinical study and implement its development plans. Many factors
could cause the Corporation’s actual results, performance or achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation,
those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties materialize or should
assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary
materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should
be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the press release are based upon what management currently believes to be reasonable
assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be
consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking
statements whether as a result of new information, future developments or otherwise except as required by law. All
forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
info@theralase.com
www.theralase.com
To view the original release, please click here
Source: Theralase Technologies Inc. (TSX Venture:TLT, OTCQX:TLTFF, FWB:TTX)
To follow Theralase Technologies Inc. on your favorite social media platform or financial websites, please click on the icons
below.
Maximum News Dissemination by FSCwire. https://www.fscwire.com
Copyright © 2018 FSCwire